Please login to the form below

Not currently logged in
Email:
Password:

ustekinumab

This page shows the latest ustekinumab news and features for those working in and with pharma, biotech and healthcare.

UK, Germany back routine use of J&J’s Tremfya

UK, Germany back routine use of J&J’s Tremfya

Tremfya (guselkumab) is a follow-up to J&J’s IL-23/IL-12 inhibitor Stelara (ustekinumab) that rakes in blockbuster revenues but is facing the threat of competition from newer

Latest news

More from news
Approximately 5 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics